$30.05
-2.1%MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Wall Street analysts project that MBX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 60.33, with estimates ranging from a low of 18.00 to a high of 88.00.
The consensus 1-year price target stands at 60.33, with estimates ranging from a low of 18.00 to a high of 88.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Significant contraction projected—major business challenges or industry disruption likely.
Reasonable estimate spread indicates general agreement with normal forecast variance.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $16.13M and sold $2.14M worth of MBX shares, resulting in $14.00M of net buying activity.
18.5K
525.66K
55.8K
2.14M
-1.6M
-$1.61M
0
0.00
0
0.00
+0
+$0
989.5K
15.61M
0
0.00
+15.6M
+$15.61M
0
0.00
0
0.00
+0
+$0
Heron Patrick J
Director, 10 Percent Owner:
$12.00M
Hoerter Steven L.
Director
$2.74M
Hawryluk P. Kent
Director, Officer: President & Ceo
$1.39M
Azoulay Salomon
Officer: Chief Medical Officer
$2.12M
Hawryluk P. Kent
Director, Officer: President & Ceo
$18K
Strong bullish signal with $14.00M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Continue your MBX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.